Senate Democrats were 1 vote short of overturning the Trump administration's expansion of short-term health plans; Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel; Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019.
Democrats forced a vote on the Trump administration’s expansion of short-term health insurance plans that do not have to comply with Affordable Care Act (ACA) regulations. However, they fell short of overturning the expansion of these plans by just 1 vote, according to The Washington Post. Democrats voted unanimously to overturn the administration rule and also brought in a vote from Senator Susan Collins, R-Maine, but they would have needed a second Republican vote in order to pass the legislation. In addition, President Donald Trump had already threatened to veto the measure if it reached his desk.
Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel. Reuters reported that the panel ruled Celltrion’s biosimilar was highly similar to the reference biologic. In February, the FDA had declined to approve the proposed biosimilar, citing a manufacturing issue. The FDA usually follows the advice of its advisory panels.
As more insurers are able to find profits in the ACA marketplaces, they have been expanding their participation. Insurer Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019, according to Fierce Healthcare. The company had increased revenue 13% at the end of the first quarter in 2018. In June, Molina Healthcare and Oscar Insurance reported they were entering new states.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen